In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions

British Journal of Dermatology

Volumn 168, Issue 3, 2013, Pages 539-549

  Polak, M E ^a   Belgi, G ^a,b   McGuire, C ^a   Pickard, C ^a   Healy, E ^a,b   Friedmann, P S ^a,b   Ardern Jones, M R ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; IMMUNOASSAY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOASSAY; INTERFERON-GAMMA; INTERLEUKIN-4; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84882280172     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12109     Document Type: Article

References (36)

1. Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672-83.
2. Sassolas B, Haddad C, Mockenhaupt M et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-8.
3. Romano A, Blanca M, Torres MJ et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004;59:1153-60.
4. Aberer W, Kranke B. Provocation tests in drug hypersensitivity. Immunol Allergy Clin North Am 2009;29:567-84.
5. Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med 2012;366:2492-501.
6. Padial A, Antunez C, Blanca-Lopez N et al. Non-immediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy 2008;38:822-8.
7. Mirakian R, Ewan PW, Durham SR et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009;39:43-61.
8. Santiago F, Goncalo M, Vieira R et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010;62:47-53.
9. Wolkenstein P, Chosidow O, Flechet ML et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996;35:234-6.
10. Barbaud A, Reichert-Penetrat S, Trechot P et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998;139:49-58.
11. Nassif A, Bensussan A, Dorothee G et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002;118:728-33.
12. Lochmatter P, Beeler A, Kawabata TT et al. Drug-specific in vitro release of IL-2, IL-5, IL-13 and IFN-gamma in patients with delayed-type drug hypersensitivity. Allergy 2009;64:1269-78.
13. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809-20.
14. Kano Y, Hirahara K, Mitsuyama Y et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007;62:1439-44.
15. Sachs B, Erdmann S, Malte Baron J et al. Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 2002;32:736-44.
16. Rozieres A, Hennino A, Rodet K et al. Detection and quantification of drug-specific T cells in penicillin allergy. Allergy 2009;64:534-42.
17. Halevy S, Grossman N. Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release. Isr Med Assoc J 2008;10:865-8.
18. Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J Am Acad Dermatol 2005;52:254-61.
19. Nishio D, Izu K, Kabashima K et al. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci 2007;48:25-33.
20. Lebrec H, Kerdine S, Gaspard I et al. Th (1)/Th (2) responses to drugs. Toxicology 2001;158:25-9.
21. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.
22. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
23. Polak ME, Newell L, Taraban VY et al. CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells. J Invest Dermatol 2012;132:1636-44.
24. Pickard C, Smith AM, Cooper H et al. Investigation of mechanisms underlying the T-cell response to the hapten 2, 4-dinitrochlorobenzene. J Invest Dermatol 2007;127:630-7.
25. Beeler A, Engler O, Gerber BO et al. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006;117:455-62.
26. Pichler WJ. Predicting drug hypersensitivity by in vitro tests. ALTEX 2007;24 Spec no: 49-52.
27. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27:175-81.
28. Luque I, Leyva L, Jose Torres M et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001;56:611-18.
29. Kuechler PC, Britschgi M, Schmid S et al. Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 2004;59:613-22.
30. Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001;31:1398-408.
31. Schnyder B, Burkhart C, Schnyder-Frutig K et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000;164:6647-54.
32. Naisbitt DJ, Britschgi M, Wong G et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003;63:732-41.
33. Naisbitt DJ, Farrell J, Wong G et al. Characterization of drugspecific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393-403.
34. Zawodniak A, Lochmatter P, Yerly D et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 2010;65:376-84.
35. Wu Y, Farrell J, Pirmohamed M et al. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+ CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-81.
36. Roujeau JC, Albengres E, Moritz S et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985;78:22-4.